Novel piperazinyl derivatives with Anti-Hyperalgesic, anti-allodynic and anti-inflammatory activities useful for the treatment of neuropathic pain

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 11, Issue 2, 2012, Pages 182-190

  Sharma, Monika ^a   Dash, Shraddha Suman ^a   Matharasala, Gangadhar ^a   Deekshith, Vanamala ^a   Sriram, Dharmarajan ^a   Yogeeswari, Perumal ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Antiallodynic; Antihyperalgesic; Carrageenan; DPPH; Neuropathic pain; Nitric oxide

Indexed keywords

1 (3 CARBOXYPYRIDYL 2) 2 PHENYL 4 METHYLPIPERAZINE; 1 (3 CYANOPYRIDYL 2) 2 PHENYL 4 METHYLPIPERAZINE; 1, 1 DIPHENYL 2 PICRYLHYDRAZYL; ACETIC ACID; CARRAGEENAN; FORMALDEHYDE; N (2,4 DIBROMOPHENYL) 2 (4 METHYL 2 PHENYLPIPERAZIN 1 YL) NICOTINAMIDE; N (2,4 DICHLOROPHENYL) 2 (4 METHYL 2 PHENYLPIPERAZIN 1 YL) NICOTINAMIDE; N (2,4 DIFLUOROPHENYL) 2 (4 METHYL 2 PHENYLPIPERAZIN 1 YL) NICOTINAMIDE; N (2,4 DIMETHYLPHENYL) 2 (4 METHYL 2 PHENYLPIPERAZIN 1 YL) NICOTINAMIDE; N (2,5 DIMETHYLPHENYL) 2 (4 METHYL 2 PHENYLPIPERAZIN 1 YL) NICOTINAMIDE; N (2,6 DIETHYLPHENYL) 2 (4 METHYL 2 PHENYLPIPERAZIN 1 YL) NICOTINAMIDE; N (2,6 DIMETHYLPHENYL) 2 (4 METHYL 2 PHENYLPIPERAZIN 1 YL) NICOTINAMIDE; N (4 BROMOPHENYL) 2 (4 METHYL 2 PHENYLPIPERAZIN 1 YL) NICOTINAMIDE; N (4 CHLOROPHENYL) 2 (4 METHYL 2 PHENYLPIPERAZIN 1YL) NICOTINAMIDE; N (4 FLUOROPHENYL) 2 (4 METHYL 2 PHENYLPIPERAZIN 1 YL) NICOTINAMIDE; NITRATE; NITRITE; NITROGEN; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG PURIFICATION; HYPERALGESIA; MONONEUROPATHY; MOTOR DYSFUNCTION; MOUSE; NERVE INJURY; NEUROPATHIC PAIN; NEUROTOXICITY; NITROSATIVE STRESS; NOCICEPTION; NONHUMAN; OXIDATIVE STRESS; PAIN ASSESSMENT; PAW EDEMA; RAT; WRITHING TEST;

ANIMALS; ANTI-INFLAMMATORY AGENTS; FEMALE; HYPERALGESIA; MALE; MICE; NEURALGIA; NIACINAMIDE; PIPERAZINES; RATS; RATS, WISTAR;

EID: 84870263235     PISSN: 18715230     EISSN: 1875614X     Source Type: Journal    
DOI: 10.2174/187152312803305704     Document Type: Article

References (34)

1. Yogeeswari, P.; Ragavendran, J.V.; Sriram, D. Neuropathic pain: strategies in drug discovery and treatment. Exp. Opin. Drug. Discov., 2007, 2(2), 169-184.
2. Zimmermann, M. Pathobiology of neuropathic pain. Eur. J. Pharmacol., 2001, 429(1-3), 23-37.
3. Hansson, P.; Lacerenza, M.; Marchettini, P. Aspects of clinical and experimental neuropathic pain: the clinical perspective. In: Neuropathic pain: Pathophysiology and treatment, Hansson, P.T.; Fields, H.L.; Hill, R.G.; Marchettini, P., Ed.; International Association for the Study of Pain Press: Seattle, 2001; Vol. 21, 1-18.
4. Jensen, T.S.; Baron, R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain, 2003, 102(1-2), 1-8.
5. McQuay, H.; Carroll, D.; Jadad, A.R.; Wiffen, P.; Moore, A. Anticonvulsant drugs for the management of pain: A systematic review. Br. Med. J., 1995, 311(7012), 1047-1052.
6. McQuay, H.J.; Tramer, M.; Nye, B.A.; Carroll, D.; Wiffen, P.J.; Moore, R.A. A systematic review of antidepressants in neuropathic pain. Pain, 1996, 68(2-3), 217-227.
7. Yogeeswari, P.; Ragavendran, J.V.; Sriram, D. An update on GABA analogs for CNS drug discovery, Rec. Pat. CNS Drug Discov., 2006, 1(1), 113-118.
8. Parsons, C.G. NMDA receptors as targets for drug action in neuropathic pain. Eur. J. Pharmacol. 2001; 429(1-7), 71-78.
9. Portenoy, R.K. Chronic opioid therapy in non-malignant pain. J. Pain Symptom Manage., 1990; 5(1), 46-62.
10. Sindrup, S.H.; Jensen, T.S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain, 1999, 83(3), 389-400.
11. Epstein, J.B.; Marcoe, J.H. Topical application of capsaicin for treatment of oral neuropathic pain and trigeminal neuralgia. Oral Surg. Oral Med. Oral Pathol., 1994, 77(2), 135-140.
12. Nelson, J.C. Safety and tolerability of the new antidepressants. J. Clin. Psychiatry, 1997, 58(6), 26-31.
13. De Boer, T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol., 1995, 10(4), 19-23.
14. Zhu, J.; Wei, X.; Liu, J.; Hu, Y.; Xu, J. Interaction of glia activation and neurotransmission in hippocampus of neuropathic rats treated with mirtazapine. Exp. Clin. Psychopharmacol., 2009, 17(3), 198-203.
15. Holm, K.; Markham, A. Mirtazapine: A review of its use in major depression. Drugs, 1999, 57(4), 607-631.
16. Srinivasa Rao, D.V.N.; Dandala, R.; Handa, V.K.; Sivakumaran, M.; Raghava Reddy, A.V.; Naidu, A. Improved synthesis of mirtazapine, Organic preparations and procedures International: New J.r Organ. Synthesis, 2005, 39(4), 399-402.
17. Hoffmann-Emery, F.; Hilpert, H.; Scalone, M.; Waldmeier, P. Efficient synthesis of novel NK1 receptor antagonists: Selective 1,4-addition of grignard reagents to 6-chloronicotinic acid derivatives, J. Org. Chem., 2006, 71(5), 2000-2008.
18. Nilsson, M.; Zhou, X.X.; Oden, L.; Classon, B.; Noren, R.; Grabowska, U.; Jackson, P.; Fallon, P.; Carr, A.; Liley, M.; Tozer, M.; Johnson, T.; Diaz, V.; Crespo P.; Kangametsa, J.; Bonnaud, T. Cysteine protease inhibitors, PCT 066180, July 21, 2005.
19. Cahilla, C.M.; Coderre, T.J. Attenuation of hyperalgesia in a rat model of neuropathic pain after intrathecal pre- or post-treatment with a neurokinin-1 antagonist. Pain, 2002, 95(3), 277-285.
20. Gonzalez, M.I.; Field, M.J.; Hughes, J.; Singh, L. Evaluation of selective NK(1) receptor antagonist CI-1021 in animal models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther., 2000, 294(2), 444-450.
21. Barclay, J.; Clark, A.K.; Ganju, P.; Gentry, C.; Patel, S.; Wotherspoon, G.; Buxton, F.; Song, C.; Ullah, J.; Winter, J.; Fox, A.; Bevan, S.; Malcangio, M. Role of the cysteine protease cathepsin S in neuropathic hyperalgesia, Pain, 2007, 130(3), 225-234.
22. Dunham, N.W.; Miya, T.S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc. Sci. Eds., 1957, 46, 208-209.
23. Siegmund, E.A.; Cadmus, R.A. A method for evaluating both nonnarcotic and narcotic analgesics. Proc. Soc. Exp. Biol., 1957, 95, 729-731.
24. Coderre, T.J.; Melzack, R.J. The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. J. Neurosci., 1992, 12, 3665-3670.
25. Bennett, G.J.; Xie, Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain, 1998, 33, 87-107.
26. Garth, T.; Whiteside, J.H.; Jamie, B.; Lilly, M.; Michelle, P.; Susan, G.; Katharine, W. Pharmacological characterisation of a rat model of incisional pain. Br. J. Pharmacol., 2004, 141, 85-91.
27. Choi, Y.; Yoon, Y.W.; Na, H.S.; Kim, S.H.; Chung, J.M. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain, 1994, 59, 369-376.
28. Eliav, E.; Herzberg, U.; Ruda, M.A.; Bennett, G.J. Neuropathic pain from an experimental neuritis of the rat sciatic nerve. Pain, 1999, 83, 169-182.
29. Caudle, R.M.; Mannes, A.J.; Benoliel, R.; Eliav, E.; Iadarola, M.J. Intrathecally administered cholera toxin blocks allodynia and hyperalgesia in persistent pain models. J. Pain, 2001, 2, 118-127.
30. Randall, L.O.; Selitto, J.J. A method for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn. Ther., 1957, 111, 409-419.
31. Da Silva, K.A.; Manjavachi, M.N.; Paszcuk, A.F.; Pivatto, M.; Viegas, C. Jr.; Bolzani, V.S.; Calixto, J.B. Plant derived alkaloid (-)-cassine induces anti-inflammatory and anti-hyperalgesics effects in both acute and chronic inflammatory and neuropathic pain models. Neuropharmacology, 2012, 62, 967-977.
32. Padi, S.S.V.; Kulkarni, S.K. Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms. Eur. J. Pharmacol., 2008, 601, 79-87.
33. Mellors, A., Tappel, A.J. The inhibition of mitochondrial peroxidation by ubiquinone and ubiquinol. Biol. Chem., 1966, 241, 4353-4356.
34. Okuda, K.; Sakurada, C.; Takahashi, M.; Yamada, T.; Sakurada, T. Characterization of nociceptive responses and spinal releases of nitric oxide metabolites and glutamate evoked by different concentrations of formalin in rats. Pain, 2001, 92, 107-115.